Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Core Viewpoint - Oculis Holding AG has announced an underwritten offering of 5,000,000 ordinary shares priced at $20.00 per share, aiming for total gross proceeds of$100 million to support its clinical development pipeline and general corporate purposes [1][3]. Group 1: Offering Details - The offering is oversubscribed and is expected to close on or about February 18, 2025, pending customary closing conditions [2]. - The new shares will be issued from the Company's existing capital band, increasing the total number of registered shares to 53,943,700 [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the clinical development of the neuroprotective candidate Privosegtor (OCS-05) and for working capital and general corporate purposes [3]. Group 3: Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema and Licaminlimab (OCS-02) for dry eye disease [5].